Creating Healthier Communities’ National Board of Directors


Joy A. Lewis, American Hospital Association executive, elected to CHC: Creating Healthier Communities’ National Board of Directors

“Together, we can work to promote the conditions where all individuals have a fair and just opportunity to reach their highest potential for health and overall well-being.”

CHC: Creating Healthier Communities, a nationwide nonprofit that addresses the barriers to good health and equity, today announced that Joy A. Lewis was unanimously elected to its national board of directors.

“We’re honored to have Joy Lewis join the board,” said Thomas G. Bognanno, president and CEO at CHC. “Her significant expertise in health equity will help us accelerate our mission and continue to advance better health and wellbeing for all people.”

Joy A. Lewis, MSW, MPH, is senior vice president, health equity strategies and executive director, Institute for Diversity and Health Equity at the American Hospital Association (AHA). In her dual roles, Lewis has broad oversight for several key association priorities and functions related to diversity, health equity and inclusion to support and build healthy communities. She also serves as a member of the executive management team of the AHA.

Before joining the AHA, Lewis held several positions over almost two decades at Kaiser Permanente in CA.

“I’m proud to join CHC’s board,” said Joy A. Lewis, board director at CHC. “Together, we can work to promote the conditions where all individuals have a fair and just opportunity to reach their highest potential for health and overall well-being.”

Lewis sits on the board of directors for the Institute for Clinical and Economic Review (ICER) and serves on several committees including the AAMC’s Health Workforce Research Committee and Bristol Myers Squibb Foundation Expert Advisory Committee. Outside of work, she fuels her passion for the arts by serving as a board member of Round House Theatre located in Bethesda, MD. Joy holds a bachelor’s degree in psychology and sociology from Wesleyan University, and dual master’s degrees in social work from Howard University and public health from the University of California – Los Angeles.

About CHC: Creating Healthier Communities

CHC: Creating Healthier Communities brings nonprofits, businesses, and communities together around a shared commitment to better health and wellbeing. For more than 65 years, CHC has worked with partners to address the barriers to good health and equity and create resilient communities where everyone can thrive. CHC’s role is to advance equity, enhance the capacity of nonprofit organizations, connect and convene diverse stakeholders, and harness collective resources and programs to activate collaborations that address root causes, increase impact, and improve the health of our communities. Join us at chcimpact.org or @chcimpact.

Share article on social media or email:

Cynerio Joins IBM Security App Exchange Community


News Image

IBM QRadar and Cynerio together give healthcare security teams the visibility and intelligence they need to find and block potential attacker pathways on connected devices.

Cynerio, a leading provider of healthcare IoT cybersecurity, today announced an integration with IBM Security QRadar SIEM. Cynerio’s integrations with IBM QRadar are designed to help to safely expedite risk management and security incident response in healthcare environments.

Patient care has seen incredible improvements due to the data, insight, and timeliness provided by connected medical devices. However, as the footprint of these devices in hospitals expands, so do the number of threats, vulnerabilities, and attacker pathways towards them. In the wake of the recent pandemic, healthcare has suffered a relentless onslaught of ransomware attacks and data breaches, with nearly a quarter of those attacks originating on a connected medical or IoT device. The inherent vulnerabilities of IoT devices, which often can’t be secured through traditional IT security tools, have made hospitals and healthcare facilities lucrative targets for increasingly sophisticated threat actors.

To help protect these medical and connected device environments, data from the Cynerio platform can now feed into IBM QRadar SIEM, bringing together IBM’s risk identification and security event monitoring with Cynerio’s medical-specific and contextual device data. This integration allows customers increased visibility into risks and attacks in their IoT and IoMT environments within QRadar’s “single pane of glass” that many organizations already leverage to respond to risk across their IT infrastructure.

“Hospital security professionals increasingly need solutions that will go beyond taking a simple inventory of all their connected devices and actually streamline the process for remediating the critical device risks that attackers are increasingly using as entry and pivot points,” said Daniel Brodie, CTO and co-founder at Cynerio. “IBM QRadar and Cynerio together give healthcare security teams the visibility and intelligence they need to find and block potential attacker pathways on connected devices.”

The new Cynerio-IBM QRadar integration is freely available to the security community through IBM Security App Exchange, a marketplace where developers across the industry can share applications based on IBM Security technologies. As threats are evolving faster than ever, collaborative development amongst the security community will help organizations adapt quickly and speed innovation in the fight against cybercrime.

For more information, please visit the IBM QRadar website at http://ibm.com/qradar or the Cynerio Website at http://www.cynerio.com/partners. A datasheet about the integration can be found here.

About Cynerio

Cynerio is the one-stop-shop Healthcare IoT security platform. With solutions that cater to healthcare’s every IoT need – from Enterprise IoT to OT and IoMT – we promote cross-organizational alignment and provide hospitals the control, foresight, and adaptability they require to stay cyber-secure in a constantly evolving threatscape. We empower healthcare organizations to stay compliant and proactively manage every connection on their own terms with real-time IoT attack detection & response and rapid risk reduction tools, so that they can focus on a hospital’s top priority: delivering quality patient care. For more information visit http://www.cynerio.com, or follow Cynerio on Facebook, Twitter, and LinkedIn. For more information about the integration email us at IBM@Cynerio.com.

Share article on social media or email:



ASI partners with Intact to Develop Technical Infrastructure for Cannabis Safety and Quality Audit


“We strongly feel that Intact is the right partner for us to take the next step in becoming a recognized standard setter in the cannabis and cannabis-adjacent industries. Our goal is to create a better, safer and more sustainable industry,” said Tyler Williams, Chief Technical Officer of CSQ.

In 2020, ASI launched the Cannabis Safety & Quality (CSQ) Standards to promote industry best practices and improve the overall safety and quality of cannabis and cannabis-infused products in the market. ASI has now commissioned Intact to develop the CSQ standard setter platform and provide audit and certification technologies to further develop CSQ and enable its infrastructure. The standard setter platform will provide the core infrastructure enabling stability, consistency, and quality of the CSQ standard and its continued growth.

Intact, the international software provider, specializes in audit, certification, and standards industry solutions. The company has demonstrated its expertise in building standard setter infrastructures through collaborations with the GRMA, IFS, and IAQG, among others. The partnership with ASI will accelerate the professionalization of the CSQ ecosystem to drive the safety and quality of the cannabis industry forward.

“We strongly feel that Intact is the right partner for us to take the next step in becoming a recognized standard setter in the cannabis and cannabis-adjacent industries. Our goal is to create a better, safer and more sustainable industry. State-of-the-art infrastructure is essential for transparent and traceable auditing to achieve that goal. Intact has proven time and again that it can provide such systems on a global scale. We are excited to have them on board for this project,” said Tyler Williams, Chief Technical Officer of CSQ.

Intact is equally proud of this new partnership. Jake Lewin, CEO of Intact US, states, “We are very excited to partner with ASI on this groundbreaking project. The cannabis industry is one of the fastest-growing sectors in the standards space. CSQ’s goal to improve the regulation of the industry will not only increase safety and quality across the entire sector but ultimately benefit the well-being of consumers across the nation. We support their mission and cannot wait to get to work building a future-proof infrastructure.”

Intact and ASI will start work on the new CSQ infrastructure in early 2022. The CSQ platform will be based on Intact’s audit and certification software, the Intact Platform, and will launch in 2022. ASI is slated to adopt the Intact Platform in 2023.

About Intact – http://www.intact-systems.com

Intact is the market leader in audit, certification, and standard management with its two main products, the Intact Platform and Intact Analytics. Their solutions help customers worldwide boost their efficiency and profitability while assuring the highest possible safety and quality of products, services, and qualifications. Founded in 2001 in Austria, Intact develops software solutions that guarantee quality assurance in the food industry. Today, Intact has seven global offices and sales partners in Austria, the USA, Switzerland, the UK, Germany, and Australia and is used across management, food, and other certification sectors.

About ASI – https://asifood.com/

ASI Food Safety is a provider of independent third-party certification, inspection and training services. Based in Missouri and serving clients nationally, ASI has been providing farm-to-fork safety solutions, such as third-party safety & quality certifications and inspections, consulting and training to the food industry since the 1940s. ASI’s innovative, reliable and trusted food safety and quality solutions assist customers in minimizing risk, reducing recalls, eliminating foodborne illness, and protecting their brand and the health and well-being of their customers.

About CSQ – https://csqcertification.com

The Cannabis Safety & Quality (CSQ) Standards were launched in 2020 to promote industry best practices and improve the overall safety and quality of cannabis and cannabis-infused products in the market. The CSQ Certification Program and applicable standards were built around both the ISO/IEC 17067 and the Global Food Safety Initiative (GFSI) Benchmarking requirements. Each standard has been developed by industry professionals and stakeholders to meet industry, customers, and regulatory requirements from seed-to-sale. Sites who achieve the CSQ certification will prove to their customers that they are fully committed to supplying only the safest and highest quality products on the market.

###

Share article on social media or email:

The Top 25 Women Leaders in Consulting for 2022


The Consulting Report is pleased to announce The Top 25 Women Leaders in Consulting for 2022. Through their various roles, these exceptional women have led their firms with insights and strategies across sectors from technology to healthcare, to financial services, as well as other sectors. They have earned their positions and place among the best in the industry by advancing the objectives of their clients and consistently driving outstanding results.

Kristen Soles of CohnReznick delivers strategic risk management and technology solutions that help organizations define their visions, solve critical business issues, and achieve positive outcomes during times of opportunity, transition, or crisis. Meanwhile, FTI Consulting’s Sophie Ross specializes in helping clients manage their overall e-discovery and review through predictable pricing models and by simplifying the multiple layers of discovery management. And Lan Guan of Accenture has led an array of analytics projects featuring customer segmentation and profiling, target marketing, predictive modeling, and business forecasting to enhance clients’ marketing efforts and improve the bottom line.

Amid a talented pool of nominees, these women set themselves apart based on their performance, their contributions to their particular area of expertise, and their reputation among their peers and the broader consulting industry. Please join us in celebrating the accomplishments of The Top 25 Women Leaders in Consulting for 2022.

Annette Rippert (Accenture), Martha Carter (Teneo), Kristen Soles (CohnReznick), Linda Blair (Deloitte Consulting), Sophie Ross (FTI Consulting), Lan Guan (Accenture), Amanda Adler (Bain & Company), Nive Bhagat (Capgemini), Claudine Cohen (CohnReznick), Srimathi Shivashankar (HCL Technologies), Teresa Espírito Santo (Boston Consulting Group), Karen Dahut (Booz Allen Hamilton), Michelle Seale (PricewaterhouseCoopers), Marie Sylla-Dixon (Raytheon Technologies), Beth Howen (Atos), Victoria Cerami (Cerami & Associates, Inc.), Quay Kester (Evoke Research And Consulting), Amy Gilliland (General Dynamics Information Technology), Jacqueline Akerblom (Grant Thornton LLP), Anne O’Donnell (Procorre), Hilary Thomas (PA Consulting), Janel Firestein (Clarkston Consulting), Cathy Arnett (TRC Companies, Inc.), Toya Asbury (Alvarez & Marsal).

The full article can be read at https://www.theconsultingreport.com

About The Consulting Report

The Consulting Report is a comprehensive source for market research and insights, business news, investment activity, and corporate actions related to the consulting sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on management consulting and the various companies, executives and investors that make up the sector.

Share article on social media or email:

The Top 25 Biotech CEOs of 2022


The Healthcare Technology Report is pleased to announce The Top 25 Biotech CEOs of 2022. Over the past year, these leading biotechnology executives and their organizations have demonstrated ingenuity, skill, and perseverance in solving tremendous challenges. The specialties of this year’s CEOs and their companies run the gamut from gene therapy to vaccine development, cancer treatment, proteomics, mRNA-based therapeutics, and much more. Many of the awardees have also found success in raising significant amounts of funding for their companies, which enables them to continue to have positive impact on the biotechnology field for years to come.

Through their tireless work, these CEOs have succeeded in advancing research and bringing breakthrough drugs and treatments to market. For instance, Franz-Werner Haas and his company CureVac are currently focused on the development of its second-generation mRNA COVID-19 vaccine candidate, CV2CoV, in collaboration with GSK. Meanwhile, Dr. Roy Smythe and SomaLogic have leveraged artificial intelligence and machine learning to develop its first-in-class, high-plex proteomics SomaSignal™ tests, which are redefining diagnostics in precision medicine. And the diverse pipeline of RNA vaccines and therapeutics of Joseph Payne and Arcturus Therapeutics includes programs pursuing COVID-19 and flu vaccines, rare diseases, Hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and glycogen storage disease type III.

One achievement all of our honorees share is the notable contributions they have made towards advancing the biotechnology industry. From hundreds of nominees, these executives stood out for their unflagging commitment to improving lives through the advancement of medicine. Please join us in recognizing the accomplishments of The Top 25 Biotech CEOs of 2022.

Emma Walmsley (GlaxoSmithKline), Charles Brown (LifeLabs Medical Laboratory), Dr. Emil Kakkis (Ultragenyx Pharmaceutical), Franz-Werner Haas (CureVac), Dr. Roy Smythe (SomaLogic), Paul Dabrowski (Synthego Corporation), Joseph Payne (Arcturus Therapeutics), Scott Hutton (Biodesix), Gaurav Shah (Rocket Pharmaceuticals), Norman Sharples (COPAN Diagnostics), Dr. Oguzhan Atay (BillionToOne), Thomas Ybert (DNA Script), Dr. Scott Braunstein (Marinus Pharmaceuticals), Sarah Boyce (Avidity Biosciences), Todd Zavodnick (Dermavent Sciences), Alexander Lorestani (Geltor), John Vitalie (Aizon), Dr. Bobak Azamian (Tarsus Pharmaceuticals), Dr. Joanne Smith-Farrell (Be Biopharma), Andrew Barnell (Geneoscopy), Dwight Egan (Co-Diagnostics), Charles Fisher (Unlearn.AI), James Peyer (Cambrian Biopharma), Alex Martin (Palladio Biosciences), Scott Megill (Coriell Life Sciences), Dr. Christopher Thanos (Actym Therapeutics), Thurein Htoo (Qlaris Bio).

The full article can be read at https://thehealthcaretechnologyreport.com/

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers and media professionals highly knowledgeable on healthcare technology and the various companies, executives and investors that make up the sector.

Share article on social media or email:

The Academy of Oncology Nurse & Patient Navigators Voices Support for Cancer Patient Infusions That Might Enhance Protection Against COVID-19


In the spirit of upholding the patient navigation competency that directs navigators to “facilitate patient-centered care that is compassionate, appropriate, and effective for the treatment of cancer and the promotion of health,” the Academy of Oncology Nurse & Patient Navigators (AONN+) Policy and Advocacy committee signed a letter this week addressed to President Joe Biden. The letter, created by the Cancer Leadership Council, focused on the special needs of cancer patients and other immune-compromised individuals during the COVID-19 pandemic and urged action to increase the supply and improve the distribution of monoclonal antibodies and antiviral treatments for pre-exposure prophylaxis and treatment of COVID-19 in immune-compromised individuals.

Some cancer patients are less likely than other people to enjoy the protections provided by the Covid vaccines. For example, blood cancer patients’ antibody levels may not be as strong as those in fully vaccinated, healthy adults, and this makes them more susceptible to a COVID-19 breakthrough infection. Their risk is that blood cancers attack the immune system since their cancer arises in cells that create antibody-producing cells. Then, the drugs that attack the leukemia, lymphoma, and multiple myeloma cancer remove not just malignant cells but also benign immune cells. Think of the bone marrow transplants that wipe out an individual’s entire immune system and the rebuilding which takes months. Bone marrow transplant patients have to start over with all vaccinations—not just against Covid—to teach those new immune cells to fight the invading coronavirus, flu, or other pathogens.

AONN+ is proud of the stance the leaders in Policy & Advocacy are taking in support of oncology patients!

February 1, 2022

The President

The White House

1600 Pennsylvania Avenue, NW

Washington, DC 20500

Dear Mr. President:

The undersigned organizations represent cancer patients, healthcare professionals, caregivers, and researchers. We are writing you about the special needs of cancer patients and other immune compromised individuals during the COVID-19 pandemic. We urge specific steps to address these needs, including increasing the supply and improving the distribution of monoclonal antibodies and antiviral treatments for pre-exposure prophylaxis and treatment of COVID-19 in immune compromised individuals.

The development of COVID-19 vaccines, monoclonal antibodies, and antivirals, and the approval of existing therapies for COVID-19 use have been impressive achievements during the pandemic. These accomplishments are a testament to the work of talented biomedical researchers and the commitment of innovative biopharmaceutical companies, as well as a statement about the benefits of public and private sector collaboration.

Despite the promise of vaccines and therapeutics, the COVID-19 virus has proven to be a daunting adversary. Patients with hematologic cancers, many cancer patients in treatment, and certain other cancer patients can offer their experience to underscore the challenges associated with COVID-19. Cancer patients, because of their disease or the treatments for their disease, may be immune compromised. This has put them at special risk of contracting COVID-19 and at risk of poor outcomes if they do contract COVID-19.

Cancer patients have sought out vaccination to protect themselves against COVID-19. Many cancer patients and other immune compromised individuals have completed a two-dose series of mRNA vaccine and have taken the third recommended dose for immune compromised individuals. They are also prepared to take a fourth vaccine booster dose.

However, many cancer patients–as a result of their immune compromised status–have a modest response to vaccines. Despite their own efforts to protect themselves against COVID-19, these patients find themselves much as they did at the beginning of the pandemic. They are vaccinated but not protected. They are closely adhering to mitigation strategies including masking, distancing, and working from home where possible. But this means that they are often unable to see family, work in some circumstances, or live as other fully vaccinated individuals can. Of great concern is the impact of their immune compromised status on their ability to undertake and successfully complete cancer treatment.

Fortunately, a monoclonal antibody combination and antivirals might offer additional tools to immune compromised cancer patients. However, the supplies of both the monoclonal antibody combination and antiviral medications are very limited, and available supplies are not consistently distributed to those who could benefit most, according to available evidence. [1]

During the pandemic, federal health officials have communicated constructively with healthcare professionals and researchers, including cancer experts, on topics related to the immune compromised and COVID-19. The approach of federal officials led to prompt action to recommend a third dose of mRNA vaccine as part of the primary series for those who are immune compromised and to the recommendation of a fourth dose as a booster dose. [2]

We urge you to continue this approach to collaboration and communication to meet the needs of the most vulnerable during the pandemic.

Although we are presenting the urgent needs of cancer patients and other immune compromised individuals who would benefit from monoclonal antibodies and antivirals but cannot obtain them, we understand that there is currently lower use of monoclonal antibody treatment among black, Asian, Hispanic, and other races with positive SARS-CoV-2 tests results relative to white and non-Hispanic patients.[3] This disparity in access must also be addressed. These disparities in access are likely experienced by cancer patients who would benefit from monoclonal antibodies. We realize that we, as healthcare professionals and patient advocates, must be engaged in efforts to address the disparities in COVID-19 treatment access. If the issues related to supply and allocation for cancer patients and other immune compromised individuals are addressed, as we urge below, we understand that important actions will still be necessary to ensure that disparities in access to monoclonal antibodies by black, Asian, and Hispanic patients–including those with cancer–are addressed.

We recommend that the federal government increase as much as possible its procurement of the monoclonal antibody combination and antiviral treatments. We also recommend that you consider an allocation and distribution system that would rely on the best available evidence regarding those who would benefit from these products. We can offer the expertise and experience of scientists, researchers, and patient advocates from our organizations to assist in this process. We can also recommend that distribution of these products to cancer centers and hospitals would help ensure better access for cancer patients who are immune compromised and who would benefit from these products.

We stand ready to offer our expertise and experience to address these difficult issues. We know that we share an interest in employing all responsible public health strategies to help vulnerable cancer patients and other immune compromised individuals survive this pandemic.

Sincerely,

Cancer Leadership Council

References:

[1] On January 24, 2022, the Food and Drug Administration (FDA) limited the use of certain monoclonal antibodies due to their limited efficacy against the omicron variant. FDA press release accessed on January 25, 2022: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron. As a result, our recommendations relate to the monoclonal antibody combination marketed as Evusheld.

[2] On January 4, 2022, the Centers for Disease Control and Prevention (CDC) updated its recommendation for a fourth dose, as a booster, for moderately or severely immunocompromised individuals. Recommendation on website accessed on January 25, 2022: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron. Despite the recommendation, immune compromised individuals are being turned away from pharmacies when they seek the fourth dose booster. Liz Szabo of Kaiser Health News reported on January 25, 2022. Article accessed on January 25, 2022: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron.

[3] Wiltz JL, Feehan AK, Molinari NM, et al. Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 – United States, March 202-August 2021. MMWR Morb Mortal Wkly Rep 2022; 71:96-102. Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 — United States, March 2020–August 2021 | MMWR (cdc.gov).

About the Academy of Oncology Nurse & Patient Navigators, Inc. (AONN+)

The Academy of Oncology Nurse & Patient Navigators, Inc. (AONN+), is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. The organization, which has more than 8900 members, was founded in 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services in order to better manage the complexities of the cancer treatment process. http://www.aonnonline.org.

About Amplity Medical Communications

Amplity Medical Communications, formerly The Lynx Group, is a premier medical communications and education company acutely focused on oncology and rare disease states. Amplity Medical Communications specializes in market access to and with advanced practice providers, patients, and their caregivers. With more than 100 years of combined senior leadership experience, Amplity Medical Communications continually creates award-winning medical education and cultivates strong relationships within proprietary brands serving patients and their caregivers, physicians, payers, nurses, pharmacists, navigators, and practice managers. Currently, Amplity Medical Communications partners with more than 50 of the top pharma and biotech companies globally.

DentalRay Now Recognized By RadSite As Part of Its National Strategy to Promote Quality-Based Cone Beam CT Imaging


News Image

“As we have begun working with RadSite over the last few months, I have become increasingly impressed with the user experience and platform they have created to help Dental, Maxillofacial, Otolaryngology, and other providers receive official accreditation,” said Caleb Manscill, CEO of DentalRay.

DentalRay, a leading dental platform in radiological interpretation, today announces that its innovative teleradiology practice has been recognized by RadSite, an official accrediting body for diagnostic imaging. RadSite’s recognition of DentalRay’s teleradiology services helps provider offices with Cone Beam CT imaging systems meet key clinical standards, including the practitioner interpretation requirements associated with RadSite’s Dental and Medical Cone Beam CT Accreditation Program. In addition, RadSite has identified DentalRay as a distribution partner to help train dental practices on the Dental and Medical Cone Beam CT Accreditation Standards.

Because RadSite is recognized by the U.S. Centers for Medicare and Medicaid Services and hundreds of private payers, accredited imaging providers can be reimbursed for certain types of imaging exams. DentalRay is now positioned to help dentists, maxillofacial surgeons and others become accredited.

Practices that were previously receiving zero reimbursements from radiological exams and their interpretations will now be able to generate new revenue streams.

“DentalRay is delighted to partner with RadSite, the nation’s leading accreditation organization for Cone Beam CT, and we are confident this partnership will result in best-in-class point of care imaging and expand access to comprehensive radiological expertise,” said Jacob D. Brown, MD, PhD, and Chief Medical Officer of DentalRay. “We share RadSite’s research-driven, value-based approach to imaging systems and healthcare, and we look forward to defining and promoting best practices for our imaging partners and referring clinicians. Like RadSite, we are a standards-based organization and our expert radiologists have completed medical school and at least four years of radiology residency. They also meet the rigorous standards of the American Board of Radiology, including training in medical physics, radiation safety, and all aspects of clinical radiology. Our standards also dictate that each of our radiologists have a full state medical license in any state where interpretations are performed, allowing us to take ownership of imaging studies and elevate the level of radiology service provided. We highly value the partnership of RadSite and its Advanced Diagnostic Imaging (ADI) Accreditation Programs as we work together to bring world class imaging to the patient at the point of care.”

“As we have begun working with RadSite over the last few months, I have become increasingly impressed with the user experience and platform they have created to help Dental, Maxillofacial, Otolaryngology, and other providers receive official accreditation,” said Caleb Manscill, CEO of DentalRay. “Because of this tremendous value, our customers are thrilled with a streamlined experience that allows them more time to focus on what matters most – providing the greatest care possible to their patients.”

RadSite’s Advanced Diagnostic Imaging (ADI) Accreditation Program (ADI) covers traditional Computed Tomography (CT), Cone Beam CT, MRI, and Nuclear Medicine (such as PET and SPECT) imaging systems. RadSite now offers five (5) accreditation programs:


  • Computed Tomography (CT) ADI, version 3.3
  • Dental Cone Beam CT ADI, version 1.2
  • Medical Cone Beam CT ADI version 1.2.
  • Magnetic Resonance Imaging (MRI) ADI, version 3.3
  • Nuclear Medicine (NucMed) ADI, version 3.3 (including SPECT and PET).

“RadSite spent several months reviewing DentalRay’s business model before recognizing the firm for its ability to educate dental offices and related practices on how to help their clients meet RadSite’s accreditation standards and how DentalRay’s radiologists interpret and report on patient imaging exams,” notes RadSite CEO, Garry Carneal, JD. “Previously, RadSite spent several years drafting and testing its Cone Beam CT Standards covering professional, quality assurance, operational and technical requirements. We are glad that DentalRay is now actively supporting RadSite’s mission to promote quality and performance-based imaging practices.” To learn more about RadSite, visit http://www.radsitequality.com.

The partnership is in effect immediately and is available for customers of DentalRay. For additional information, please reach out to caleb@dentalray.healthcare.

About DentalRay (http://www.dentalray.healthcare)

DentalRay is a leading radiology interpretation platform that provides dentists with comprehensive radiology reports within 48 hours of a radiograph. Leveraging its automated system and national network of radiologists, DentalRay is able to deliver exceptional radiological interpretations without the cumbersome processes and lengthy delays posed by traditional methods. With DentalRay, dentists are able to elevate their standard of care, decrease their risk of litigation, and get a significant ROI on their CBCT machines. To learn more about DentalRay, please contact us at (801) 251-6901 or info@dentalray.healthcare.

About RadSite™ (http://www.RadSiteQuality.com)

Founded in 2005, RadSite’s mission is to promote performance and quality-based practices for imaging systems across the U.S. and its territories. RadSite is recognized by the U.S. Centers for Medicare and Medicaid Services (CMS) as an official accreditation organization under the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008. RadSite also is recognized by over 300 payers and has accredited over 1,000 imaging suppliers. RadSite’s programs help assess, track, and report imaging trends to enhance imaging procedures and outcomes. RadSite also offers educational programs, publishes issue briefs, and underwrites research on a complimentary basis to raise awareness of patient safety issues and to promote best practices. The organization is governed by an independent advisory board and committee system, which is open to a wide range of volunteers to ensure transparency and accountability. To learn more about RadSite, please contact us at (443) 440-6007 or info@radsitequality.com.

Share article on social media or email:

South County Psychiatry Expands, Opens New Practice Location in Connecticut Serving Southeastern CT


South County Psychiatry in North Kingstown, RI

Just two years after opening South County Psychiatry in North Kingstown, Rhode Island, the comprehensive behavioral health practice has opened its second location, to best serve the needs of patients in southeastern Connecticut.

South County Psychiatry is dedicated to providing the region’s best evidence-based care in the communities it serves. South County Psychiatry provides psychiatric evaluations, psychotherapy, medication management, and FDA-approved transcranial magnetic stimulation (TMS).

The new Connecticut practice will be helmed by Board-Certified Psychiatric Mental Health Nurse Practitioner (PMHNP-BC) Rhonda Bessette. Bessette earned her Masters in Science of Nursing from Eastern Kentucky University. She earned her Bachelors of Science in Nursing from Southern New Hampshire University.

Bessette focuses her practice on the treatment of anxiety disorders, obsessive-compulsive disorder (OCD), major depression, attention deficit hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD). She has spent the bulk of her professional career working in adult psychiatric inpatient facilities. Bessette has prescriptive authority in Connecticut.

Bessette will be supported by the entire South County Psychiatry team of psychiatrists, physician’s assistants, psychiatric nurse practitioners, and licensed chemical dependency professionals.

Treatment for mental health conditions and neurocognitive disorders provided by South County Psychiatry typically involves psychotherapy, used in conjunction with medication, where indicated. South County Psychiatry’s physicians, nurse practitioners, and physician’s assistants oversee mental health medications, to ensure they are taken as prescribed to achieve the best therapeutic outcome.

The Connecticut office of South County Psychiatry is now accepting new patients.

About South County Psychiatry

South County Psychiatry was founded in 2019 by Anthony Gallo, MD. South County Psychiatry provides psychotherapy, including cognitive-behavioral therapy (CBT), behavioral activation therapy, and dialectical behavior therapy. For appointments in Rhode Island or Southeastern Connecticut, visit https://www.southcountypsychiatryri.com/ or call 959-666-3778.

Share article on social media or email:

AuntMinnie.com launches revamped Imaging Leaders Community with support from Delphinus Medical Technologies Inc.


AuntMinnie.com logo

We are pleased to have the support of Delphinus Medical Technologies Inc. to enable us to continue to provide this valuable content to our members as part of the Imaging Leaders Community.

Radiology portal AuntMinnie.com, part of Science and Medicine Group, today announced the relaunch of its Imaging Leaders Community with support from women’s imaging firm Delphinus Medical Technologies Inc.

The Imaging Leaders Community is a special section of AuntMinnie.com dedicated to covering the emerging trends and key opinion leaders that are reshaping medical imaging. From the emergence of value-based care to the latest regulatory changes, the Imaging Leaders Community gives radiology professionals the valuable insights they need to make their practices more efficient.

Delphinus is the developer of the SoftVue 3D Whole Breast Ultrasound Tomography System, intended to serve as an adjunct to digital mammography for screening asymptomatic women with dense tissue. SoftVue was granted premarket approval (PMA) by the U.S. Food and Drug Administration in October 2021.

“We believe our SoftVue 3D Whole Breast Ultrasound Tomography System provides a breakthrough solution for dense breast imaging, and AuntMinnie.com and the Imaging Leaders Community is an outstanding opportunity to support continuous advancement of patient care. As a dedicated resource for emerging technologies and trends, this community is a perfect fit for our innovations and the benefits they deliver,” said Mark J. Forchette, president and CEO of Delphinus Medical Technologies Inc.

“We are pleased to have the support of Delphinus Medical Technologies Inc. to enable us to continue to provide this valuable content to our members as part of the Imaging Leaders Community,” said Brian Casey, editor in chief of AuntMinnie.com. “Both AuntMinnie and Delphinus share the common goal of enabling radiology professionals to deliver better care to their patients.”

The Imaging Leaders Community is available on AuntMinnie.com at leaders.auntminnie.com.

About AuntMinnie.com

AuntMinnie.com is the leading website for news, education, and interaction for radiology professionals. Rich in timely, dynamic content and customer-centered products and services, AuntMinnie.com is designed to enhance the professional lives of its members and help them deliver better patient care. AuntMinnie.com is part of Science and Medicine Group.

About Delphinus Medical Technologies Inc.

Headquartered in Novi, MI, Delphinus Medical Technologies Inc. is a pioneering medical imaging company that has developed SoftVue, featuring the first circular array transducer technology. The patented technology is a 3D whole-breast ultrasound tomography system that delivers no radiation, requires no compression, and images the entire breast with a single scan.

Share article on social media or email:

The Vanguard Network Launches a New Global Dialogue Series for Senior Healthcare and Life Sciences Leaders


“In this interconnected world, there are unprecedented opportunities for capable leaders to succeed internationally.” said Ken Banta, founder and principal of The Vanguard Network, and a seasoned global healthcare leader himself. “I’m excited about bringing together talented individuals who want to

What does it take to be a global leader? The Vanguard Network will explore this topic in an interactive online discussion on March 2 at 8 to 9:30 PM Eastern Time. Designed for leaders who aspire to a global role, the event features international executive Richard Schatzberg, Chief Commercial Officer of NeST Technologies.

“In this interconnected world, there are unprecedented opportunities for capable leaders to succeed internationally.” said Ken Banta, founder and principal of The Vanguard Network, and a seasoned global healthcare leader himself. “I’m excited about bringing together talented individuals who want to spread their wings in a wider role.”

The 90-minute session will include an in-depth dialogue with Richard about becoming an international leader at NeST Technologies and the challenges or benefits that come with it. In addition we will host a small group simulation to solve hypothetical problems encountered in global leadership roles.

This dialogue is one of an array of membership benefits of http://www.thevanguardnetwork.com, which organizes events, publishes content and connects C-suite leaders.

Senior leaders may request an invitation to the Forum at https://www.thevanguardnetwork.com/030222

The Vanguard Network is led by Ken Banta, a top management advisor who works with CEOs and senior executives on leadership, organizational transformation and corporate positioning. Ken has helped to lead 11 successful global transformations and turnarounds, and has advised on many more. He writes regularly for HBR and is a Contributing Author of “HBR’s 10 Must Reads for CEOs.”

Vanguard’s roster of more than 100 advisors and session leaders includes David Pyott, past CEO of Allergan, Ashley McEvoy (J&J), Jeremy Levin, Chair and CEO of Ovid Therapeutics, Cameron Durrant, (Humanigen), and Tom Sabatino, GC of Tenneco and past GC of Aetna, United Airlines, Walgreens and Schering-Plough.

For more information about the Vanguard Group for Leadership, visit https://www.thevanguardnetwork.com.

Share article on social media or email:

Press Release News Wire Service